UK First Nation To Approve Pfizer-BioNTech COVID-19 Vaccine, Roll Out ‘Next Week'

December 02, 2020 06:53 PM AEDT | By Team Kalkine Media
Follow us on Google News:

In a major development, the United Kingdom on Wednesday became the first nation to approve the Pfizer-BioNTech vaccination for public use. The COVID-19 mRNA vaccine candidate will be rolled out from next week, informed UK health secretary Matt Hancock. The complete delivery fulfilment is expected by the end of 2021.

British regulator Medicines and Healthcare products Regulatory Agency (MHRA) granted a temporary authorization on the emergency supply of the jab. The decision was based on a rolling submission from clinical studies that demonstrated a 95 per cent efficacy.

US-based pharma giant Pfizer (NYSE: PFE, PFE:US) and its German research partner BioNTech SE (NASDAQ: BNTX, BNTSX:US) had shared the analysis from Phase 3 trials last month. The organizations claimed that their vaccine for SARS-CoV-2, the virus that causes the coronavirus, displayed consistent effectiveness across age, gender, race and ethnic demographics.

Both the companies are prepared to release the first doses of the vaccine in UK markets immediately, said a statement from drug maker Pfizer. They had earlier signed deals to supply 40 million doses in stages to the UK by 2020-2021.

Authorization decisions from the US Food and Drug Administration (FDA) and EU European Medicines Agency (EMA) are also expected in December.

Britain's emergency use authorization marks a historic moment in the fight against the devasting pandemic, Pfizer said in a statement.

The MHRA will now decide which priority groups will receive the first dose of the vaccine such as healthcare staff, elderly, home care residents, etc.

The Pfizer- BioNTech vaccine needs to be stored at -70°C (-94°F) and requires specialized freezers. However, Pfizer has vast expertise in cold-chain shipping and an established infrastructure to supply the vaccines.

As per preliminary projections, the combined manufacturing network of Pfizer and BioNTech can supply up to 50 million vaccine doses in 2020 and nearly 1.3 billion doses by 2021.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK